Abstract
A 36-year-old woman was diagnosed with systemic lupus erythematosus (SLE). Seven days after beginning glucocorticoid treatment, she developed reduced visual acuity, and atypical severe central serous chorioretinopathy (CSC) was confirmed. Since glucocorticoid use is an important risk factor for CSC, the PSL was reduced, tacrolimus was added, and the visual acuity improved rapidly. Reduction in glucocorticoid combined with the use of immunosuppressive agents is one option for preventing a deterioration in atypical severe CSC while still controlling SLE.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Khng CG, Yap EY, Au-Eong KG, et al. Central serous retinopathy complicating systemic lupus erythematosus: a case series. Clin Experiment Ophthalmol. 2000;28:309–13.
Haimovici R, Koh S, Gagnon DR, et al. Risk factors for central serous chorioretinopathy: a case–control study. Ophthalmology. 2004;111:244–9.
Sharma T, Shah N, Rao M, et al. Visual outcome after discontinuation of corticosteroids in atypical severe central serous chorioretinopathy. Ophthalmology. 2004;111:1708–14.
Sharma T, Badrinath SS, Gopal L, et al. Subretinal fibrosis and nonrhegmatogenous retinal detachment associated with multifocal central serous chorioretinopathy. Retina. 1998;18:23–9.
Karadimas P, Kapetanios A, Bouzas EA. Central serous chorioretinopathy after local application of glucocorticoids for skin disorders. Arch Ophthalmol. 2004;122:784–6.
Wakakura M, Song E, Ishikawa S. Corticosteroid-induced central serous chorioretinopathy. Jpn J Ophthalmol. 1997;41:180–5.
Thoelen AM, Bernasconi PP, Schmid C, et al. Central serous chorioretinopathy associated with a carcinoma of the adrenal cortex. Retina. 2000;20:98–9.
Bouzas EA, Scott MH, Mastorakos G, et al. Central serous chorioretinopathy in endogenous hypercortisolism. Arch Ophthalmol. 1993;111:1229–33.
Szeto CC, Kwan BC, Lai FM, et al. Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis. Rheumatology (Oxford). 2008;47:1678–81.
Suzuki K, Kameda H, Amano K, et al. Single center prospective study of tacrolimus efficacy and safety in the treatment of various manifestations in systemic lupus erythematosus. Rheumatol Int. 2011;31:757–63.
Kamdar NV, Erko A, Ehrlich JS, et al. Choroidopathy and kidney disease: a case report and review of the literature. Cases J. 2009;2:7425.
Nguyen QD, Uy HS, Akpek EK, et al. Choroidopathy of systemic lupus erythematosus. Lupus. 2000;9:288–98.
Aronson AJ, Ordonez NG, Diddie KR, et al. Immune-complex deposition in the eye in systemic lupus erythematosus. Arch Intern Med. 1979;139:1312–3.
Matsuo T, Nakayama T, Koyama T, et al. Multifocal pigment epithelial damages with serous retinal detachment in systemic lupus erythematosus. Ophthalmologica. 1987;195:97–102.
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Sato, H., Ito, S., Nagai, S. et al. Atypical severe central serous chorioretinopathy in a patient with systemic lupus erythematosus improved with a rapid reduction in glucocorticoid. Mod Rheumatol 23, 172–174 (2013). https://doi.org/10.1007/s10165-012-0629-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10165-012-0629-6